Cargando…
Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer
Neoantigens are ideal targets for dendritic cell (DC) vaccines. So far, only a few neoantigen-based DC vaccines have been investigated in clinical trials. Here, we reported a case of a patient with metastatic gastric cancer who received personalized neoantigen-loaded monocyte-derived dendritic cell...
Autores principales: | Guo, Zengqing, Yuan, Yuan, Chen, Chao, Lin, Jing, Ma, Qiwang, Liu, Geng, Gao, Yan, Huang, Ying, Chen, Ling, Chen, Li-Zhu, Huang, Yu-Fang, Wang, Hailun, Li, Bo, Chen, Yu, Zhang, Xi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166775/ https://www.ncbi.nlm.nih.gov/pubmed/35661819 http://dx.doi.org/10.1038/s41698-022-00279-3 |
Ejemplares similares
-
Neoantigen landscape in metastatic nasopharyngeal carcinoma
por: Lin, Mei, et al.
Publicado: (2021) -
Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021) -
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
por: Burrack, Adam L., et al.
Publicado: (2019) -
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
por: Zhang, Rui, et al.
Publicado: (2019) -
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
por: Wang, Guan, et al.
Publicado: (2020)